Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Peking Union Medical College Hospital, Beijing, Beijing Municipality Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Guangxi Medical University Cancer Hospital, Nanning, Guangxi Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Jiangsu Province Hospital, Nanjing, Jiangsu Liaoning Cancer Hospital & Institute, Shenyang, Liaoning The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Shandong Cancer Hospital, Jinan, Shandong Shanghai Chest Hospital, Shanhai, Shanghai Municipality Sichuan Cancer Hospital, Chengdu, Sichuan Tianjin Medical University Cancer Institute & Hospital, Tianjing, Tianjing The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang Zhejiang Cancer Hospital, Hangzhou, Zhejiang